1 completed, 1 recruiting, 1 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Liver Transplant Rejection: new trials by email Literature Review of Liver Transplant Rejection trials Research Report on Liver Transplant Rejection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver - Liver Diseases, Liver Cancer | Phase 1 / Phase 2 | Recruiting | AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC | 90 | 2025-06-01 | 2025-07-08 |
| Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension CFZ533, Tacrolimus - MMF - corticosteroids - Liver Transplant Rejection | Phase 2 | Terminated | Novartis Pharmaceuticals | 129 | 2019-10-07 | 2025-05-16 |
| Cell Infusion Intraportal Autologous Bone Marrow Mononuclear as Enhancer of Liver Regeneration Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments. - Liver Transplant Rejection | Phase 2 | Completed | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | 13 | 2011-03-01 | 2015-12-14 |
Fatty Liver (1) · Liver Cirrhosis (1) · Liver Diseases (1) · Liver Failure (1) · Liver Neoplasms (1)
Digestive System Diseases (1) · Digestive System Neoplasms (1) · Fibrosis (1) · Hepatic Insufficiency (1) · Neoplasms (1) · Neoplasms by Site (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
iscalimab (1)
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC (1) · Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud (1) · Novartis Pharmaceuticals (1)
Spain (2) · Argentina (1) · Belgium (1) · China (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Netherlands (1) · United States (1)
Antonio Galindo, MD (1) · Daniel Garrote, MD (1) · Francisco Javier Padillo, MD (1) · Sebastian Rufian, MD (1)
2009 (1), 2018 (1)